Attralus

Attralus is a biotech company in Naples, United States. It has raised $172.0M across 2 rounds, most recently a $56.0M Venture Round in February 2024.

Novel Pan-Amyloid Removal (PAR) Therapeutics

Headquarters
Naples, Florida
Employees
11–50
Business Model
B2B
Total Funding
$172.0M
Last Round
$56.0M Venture RoundFeb 2024
Rounds
2

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 2 funding rounds for this company. The full record is or through the API.

About

Attralus is a biopharmaceutical company developing pan-amyloid removal therapeutics intended to improve the lives of patients with systemic amyloidosis. Its pipeline of novel biologics is designed to remove toxic amyloid across all stages and types of the disease. Current treatments apply only to some amyloidosis types and reduce new amyloid formation, but they do not clear deposits already in organs that drive organ failure. Attralus is advancing therapies meant to broadly remove existing amyloid and potentially improve organ function. Its scientists have researched and developed systemic amyloidosis therapeutics for more than 25 years.

Summary

It lists 11–50 employees. It has raised $172.0M in total across 2 rounds, most recently a $56.0M Venture Round in Feb 2024.

Tech & App Stack

7 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Data from Indexed.vcUpdated
Venture RoundFinancing RoundFeb 2024
$56.0M

Sign up to see all 2 events

Funding: Series B through Venture Round. Amounts, valuations, and investors where available.

Similar Companies

Paratek PharmaceuticalsAcquired

Paratek Pharmaceuticals develops and delivers innovative treatments for serious infectious diseas...

Boston, United States201–500Biotech, Healthcare
ConvertibleTotal funding$1.8BApr 2018
Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech, Healthcare
Series DTotal funding$1.4BJun 2020
Abogen Biosciences

Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...

Suzhou, China201–500Biotech, Drug Discovery
Extension RoundTotal funding$1.2BNov 2021
Alnylam PharmaceuticalsIPO

Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...

Cambridge, United States1001–5000Biotech, Genomics
Corporate RoundTotal funding$1.0BApr 2020
Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech, Healthcare
Growth EquityTotal funding$5.1BAug 2022
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Attralus on Indexed.vc
<a href="https://indexed.vc/companies/attralus"><img src="https://indexed.vc/api/badge/company/attralus" alt="Attralus on Indexed.vc" width="260" height="76" /></a>